Literature DB >> 15863817

Olanzapine augmentation of fluoxetine in body dysmorphic disorder.

Katharine A Phillips.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863817      PMCID: PMC1613796          DOI: 10.1176/appi.ajp.162.5.1022-a

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.

Authors:  K A Phillips; R S Albertini; J M Siniscalchi; A Khan; M Robinson
Journal:  J Clin Psychiatry       Date:  2001-09       Impact factor: 4.384

2.  Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.

Authors:  J E Grant
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

3.  A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale.

Authors:  K A Phillips; E Hollander; S A Rasmussen; B R Aronowitz; C DeCaria; W K Goodman
Journal:  Psychopharmacol Bull       Date:  1997

4.  Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.

Authors:  E Hollander; A Allen; J Kwon; B Aronowitz; J Schmeidler; C Wong; D Simeon
Journal:  Arch Gen Psychiatry       Date:  1999-11

5.  Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.

Authors:  Katharine A Phillips
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

  5 in total
  12 in total

Review 1.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

Review 2.  Body dysmorphic disorder: some key issues for DSM-V.

Authors:  Katharine A Phillips; Sabine Wilhelm; Lorrin M Koran; Elizabeth R Didie; Brian A Fallon; Jamie Feusner; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

3.  Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity.

Authors:  Katharine A Phillips; Maria E Pagano; William Menard
Journal:  Ann Clin Psychiatry       Date:  2006 Oct-Dec       Impact factor: 1.567

4.  Obsessive-compulsive disorder after body dysmorphic disorder: a report of 2 cases (a man and his mother).

Authors:  Fatih Canan; Emel Kocer; Salih Yildirim; Ahmet Ataoglu
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

5.  Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive-compulsive disorder, and social phobia.

Authors:  Katharine A Phillips; Robert L Stout
Journal:  J Psychiatr Res       Date:  2005-11-23       Impact factor: 4.791

Review 6.  A review of body dysmorphic disorder and its presentation in different clinical settings.

Authors:  Amir Mufaddel; Ossama T Osman; Fadwa Almugaddam; Mohammad Jafferany
Journal:  Prim Care Companion CNS Disord       Date:  2013-07-18

7.  Pharmacotherapy for Body Dysmorphic Disorder.

Authors:  Katharine A Phillips
Journal:  Psychiatr Ann       Date:  2010-07

8.  Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.

Authors:  Ozcan Uzun; Barbaros Ozdemir
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 9.  Pharmacotherapy and psychotherapy for body dysmorphic disorder.

Authors:  Jonathan C Ipser; Candice Sander; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 10.  Body dysmorphic disorder.

Authors:  Andri S Bjornsson; Elizabeth R Didie; Katharine A Phillips
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.